These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells. Alvarado-Cruz I; Mahmoud M; Khan M; Zhao S; Oeck S; Meas R; Clairmont K; Quintana V; Zhu Y; Porciuncula A; Wyatt H; Ma S; Shyr Y; Kong Y; LoRusso PM; Laverty D; Nagel ZD; Schalper KA; Krauthammer M; Sweasy JB Biochem Pharmacol; 2021 Feb; 184():114359. PubMed ID: 33285109 [TBL] [Abstract][Full Text] [Related]
3. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192 [TBL] [Abstract][Full Text] [Related]
4. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151 [TBL] [Abstract][Full Text] [Related]
5. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825 [TBL] [Abstract][Full Text] [Related]
6. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468 [TBL] [Abstract][Full Text] [Related]
7. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer. Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912 [TBL] [Abstract][Full Text] [Related]
8. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition. Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743 [TBL] [Abstract][Full Text] [Related]
9. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Gupta T; Vinayak S; Telli M Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381 [TBL] [Abstract][Full Text] [Related]
10. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer. Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191 [TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869 [TBL] [Abstract][Full Text] [Related]
12. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway. Dong Q; Yu T; Chen B; Liu M; Sun X; Cao H; Liu K; Xu H; Wang Y; Zhuang S; Jin Z; Liang H; Hui Y; Gu Y JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937640 [TBL] [Abstract][Full Text] [Related]
13. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724 [No Abstract] [Full Text] [Related]
15. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells. Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559 [TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity. Li GL; Ding GX; Zeng L; Ming SL; Fu PF; Wang Q; Yang GY; Wang J; Chu BB J Virol; 2021 Jul; 95(16):e0076021. PubMed ID: 34037418 [TBL] [Abstract][Full Text] [Related]
18. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance. Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442 [TBL] [Abstract][Full Text] [Related]
19. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904 [TBL] [Abstract][Full Text] [Related]